Ontology highlight
ABSTRACT:
SUBMITTER: Mariaule G
PROVIDER: S-EPMC6271685 | biostudies-other | 2014 Sep
REPOSITORIES: biostudies-other
Molecules (Basel, Switzerland) 20140911 9
In the early 2000s, the anticancer drug imatinib (Glivec®) appeared on the market, exhibiting a new mode of action by selective kinase inhibition. Consequently, kinases became a validated therapeutic target, paving the way for further developments. Although these kinases have been thoroughly studied, none of the compounds commercialized since then target cyclin-dependent kinases (CDKs). Following a recent and detailed review on the subject by Galons et al., we concentrate our attention on an upd ...[more]